Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

Slides:

Advertisements

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Advertisements

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

Supplemental Figure 1 A No. at risk T T T

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Anti-Third Party CD8+ CTLs as Potent Veto Cells S Reich-Zeliger, Y Zhao, R Krauthgamer, E Bachar-Lustig, Y Reisner Immunity Volume 13, Issue 4, Pages

IFNγIL-2TNFaIL-17A CD40 L MOPP DMSO CD4+ Supplemental figure 5A SEB isotype control isotype control isotype control CD69+ A.

Spot number ; H1 Supporting Information Figure 3. MS spectra of the identified proteins.

TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Anti-CD3/Anti-CD28 Bead Stimulation Overcomes CD3.

Figure Molecular Biology of the Cell (© Garland Science 2008)

Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)

爱迪科森网上报告厅 WANGSHANGBAOGAOTING.  公司简介  发展历程  产品简介  2009 年新亮点  产品规模及内容  功能介绍及使用说明  产品特点  后台管理  制作系统  售后服务  公司资质  典型用户目录.

Suppl. Fig x106 Culture of Irradiated A-CFSE

500 mg total protein /mL S-CM 250 mg total protein /mL S-CM

From: Treatment of Refractory Whipple Disease with Interferon-γ

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

a b c d Supplemental Figure S x108 IFU 2x108 IFU 28 28

Supplemental Digital Content 2 – Figure 2

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Supplemental figure 1 A B C

Differentiation and Functions of CD8+ Effector T Cells

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

A B Supplemental Figure 1 PBMC Cervical Cytobrush

Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

Supplemental Figure 2, Ghielmetti et al

Figure 3 Differentiation and functional control of T-cell subsets

Supplemental Tables/Figures

Supplemental Figure % annexin V-stained cells mean A

Supplementary Figure 1 FSC-A SSC-A HC UC CD

The K594ScFv-SEA-D227A fusion protein targets CTL to lyse EA

Supplemental Figure 1A Pt Pt Pre-treatment

Peptide ID# Pulsed to T2-A24 Cells

Supplemental Figure untreated Rituximab Alemtuzumab

b. Bone marrow (CP) IM sensitive c. Bone marrow (CP) IM resistant

Supplemental Digital Content 2 – Figure 1

Refer to word document for this table

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%

Premal Lulla, Carlos A. Ramos Molecular Therapy

Supplemental Figure 1 Patient 2.

Double Trouble: HIV Latency and CTL Escape

Jürgen C. Becker, David Schrama Journal of Investigative Dermatology

Reh cells, 24 hours c-Myc Ac-p53 b-actin

A n.s. WT 4-1BB-/- B n.s. WT 4-1BB-/-

Volume 30, Issue 2, Pages (February 2009)

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

Volume 60, Issue 6, Pages (December 2001)

Mads Hald Andersen, Jürgen C. Becker, Per thor Straten

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Vehicle Akti 0’ 2’ 5’ 10’ 0’ 2’ 5’ 10’ AktT308 β-actin GSK3βS9 β-actin

Introduction. Activation of HIV-Specific CD8+ T Cells from HIV+ Donors by Vesatolimod.

Figure 2 Repopulation of CD19+ cells in low and high BSA patients and calculation of the BSA Repopulation of CD19+ cells in low and high BSA patients and.

Figure 3 Impact of short-term MP administration on frequency and phenotype of slanDCs and monocytes in the blood of patients with MSThe percentages of.

Celiac disease as a model for SLE

? TLR1-TLR2 TLR1-TLR2L TCR 4-1BB

Supplemental Figure S1 A B Adults Neonates Adult CD103+ DC: KdM282-90

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

Upper Zone Threshold (bpm) Lower Zone Threshold (bpm)

Cytotoxicity of p5399–107-induced CTL cells.

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

Supplementary Figure 1. The extrinsic acquisition of CD80 does not affect the cytotoxicity of Ag-specific memory CD8+ T cells. The LG and SP were obtained.

Figure 5-1 Molecular Biology of the Cell (© Garland Science 2008)

CD137 Expression Identifies Leukemia Specific CTL after in Vitro Priming of Cord Blood T Cells Previously Expanded By CD3/CD28 Co-Stimulation Jeyaraj.

Induction of NY-ESO-1-specific CD4+ and CD8+ T cell responses after in vitro presensitization with NY-ESO-1 p or Ad2/ESO. Induction of NY-ESO-1-specific.

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

FIGURE 1 WT CD2 TG CD25 CONTROL IL-2 CD3/CD28 CD3/CD28+IL

Presentation transcript:

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells 0 1 3 4 SMM Patient #2 SMM Patient #3 SMM Patient #4 0 1 3 4 0 1 3 4 Number of Multipeptide Stimulations Supplemental Figure 1A

Supplemental Figure 1B SMM Patient #1 MP-CTL % CD3+ CD4+ T Cells 0 1 3 4 SMM Patient #2 SMM Patient #3 SMM Patient #4 0 1 3 4 0 1 3 4 Number of Multipeptide Stimulations Supplemental Figure 1B